Scientific deep-dive
Lifestyle Plus the Drug
Across 98,261 veterans with type 2 diabetes, taking a GLP-1 and keeping six to eight healthy habits was associated with 43% fewer cardiovascular events than three or fewer habits and no drug. The two figures people will compare cannot be compared.
The tiresome argument about whether people should “just eat better instead” now has data from 98,261 veterans with type 2 diabetes followed across 632,543 person-years. Doing both was linked to fewer cardiovascular events than doing either. People taking a GLP-1 and keeping six to eight healthy habits had 43% fewer major cardiovascular events than people with three or fewer habits and no drug.[1]
What was measured
| Comparison | Hazard ratio |
|---|---|
| All eight low-risk lifestyle habits vs one or fewer | 0.40 (95% CI 0.30–0.54) |
| GLP-1 users vs non-users | 0.84 (95% CI 0.76–0.92) |
| GLP-1 plus six to eight habits vs three or fewer habits and no GLP-1 | 0.57 (95% CI 0.46–0.71) |
The authors’ conclusion is that combining lifestyle change with pharmacotherapy was associated with a greater reduction than either approach alone.[1]
The comparison you cannot make from this table
It is tempting to set 0.40 against 0.84 and conclude lifestyle is roughly four times more powerful than the drug. The table cannot support that comparison, and it is the misreading this study will be used for.
The rows are different contrasts. One compares the extremes of an eight-point gradient; the other compares taking a drug against not taking it.
“Eight habits versus one or fewer” contrasts the healthiest people in the dataset against the least healthy across a wide range of behaviors. “GLP-1 user versus non-user” is a single yes-or-no. Those produce numbers that cannot be ranked against each other, any more than you could compare the effect of “the top versus bottom of a scale” with “on versus off a switch”.
There is a second problem specific to lifestyle findings in observational data. Adhering to eight healthy habits is not randomly distributed. It correlates with income, housing, working hours, disability, and every other advantage that independently predicts cardiovascular outcomes. Adjustment reduces that confounding but does not remove it. Only randomization does, and lifestyle trials that count heart attacks rather than kilograms are rare; one assigned people with heart disease to a Mediterranean or a low-fat diet and followed them for seven years.
What the finding does support
- The two are not alternatives. This is the useful part. Public debate usually frames them as a choice between one and the other.
- Taking the drug does not make lifestyle irrelevant. The authors conclude that the drug combined with the habits was associated with a greater reduction in risk than either on its own.
- The drug is not a substitute for the habits, and the habits are not a reason to refuse the drug. The data support both halves of that.
- It is consistent with the randomized picture. In a four-arm trial we covered in exercise plus a GLP-1, the drug alone did nothing for physical fitness while exercise did, and the combination did most.
Frequently Asked Questions
References
- 1.Nguyen XT, Li Y, Czernichow S, et al. Combined associations of GLP-1 receptor agonists and a healthy lifestyle with cardiovascular outcomes among individuals with type 2 diabetes The Lancet Diabetes & Endocrinology. 2026. PMID: 41763234.
Compare the sellers
Related research
How Far You Can Walk
Peripheral artery disease stops people walking, and almost nothing improves it. A trial of 792 people measured actual walking distance, and the spread matters as much as the median.
6 min read
Semaglutide and Peripheral Artery Disease: The Label, the Options and Coverage
STRIDE showed semaglutide 1 mg improved walking distance in type 2 diabetes with PAD, and Novo Nordisk filed for a US label change in 2025. Ozempic's label still lists no PAD use, but PAD already counts as cardiovascular disease on the Ozempic and Wegovy labels.
7 min read
Muscle Loss: Drug Versus Dieting
Across 20 trials in 15,782 people, lean mass made up the same fraction of weight lost on incretin drugs as on dieting (p=0.42). Adding resistance training cut it from about a quarter to 17.5%.
6 min read
Metformin vs GLP-1 for Longevity: The TAME Trial Has Not Started
No trial shows metformin extends life in people without diabetes. TAME, the metformin aging trial, has no registry record and was still unfunded at last report. Semaglutide has randomized outcome data, but only in people already at high risk.
9 min read
Exercise Plus a GLP-1: What Each One Actually Changes
In a four-arm randomized trial, the drug alone produced no improvement in physical fitness. Exercise did, with or without the drug, and the strength result needs reading carefully.
6 min read
Diastasis Recti and Weight Loss: What GLP-1s, Exercise and Surgery Change
Diastasis recti is a widened seam between the ab muscles, common after pregnancy and not a hernia. What the studies show on weight as a risk factor, why a belly can still bulge after GLP-1 weight loss, how little exercise closes the gap, and surgical repair.
11 min read
Where to get GLP-1 online, safely: sellers our editors have checked
These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
WellMedRx
Comparing compounded and brand GLP-1 plans with a published state list
From $49/mo
Get started →altRX
Compounded semaglutide from $89/month at the same price at every dose
From $89/mo
Get started →CoreAge Rx
Flat-priced compounded semaglutide at $79 a month, any dose
From $79/mo
Get started →